ALN-RSV01: Completed Phase IIb enrollment

Alnylam completed enrollment of about 90 RSV-infected lung transplant patients in the double-blind, placebo-controlled, international Phase IIb trial evaluating 0.6 mg/kg inhaled ALN-RSV01 once daily ...